Market Closed - Xetra 16:35:04 14/06/2024 BST 5-day change 1st Jan Change
8.4 EUR +0.72% Intraday chart for Evotec SE -4.87% -60.53%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Evotec benefits modestly from research payment DP
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb CI
EVOTEC : RBC remains its Buy rating ZD
Evotec Partners With French Institutions, Company to Research Obesity MT
Evotec Joins Collaboration to Identify New Therapies for Obesity, Metabolic Diseases MT
Evotec, Inserm, Lille Evotec, Inserm, Lille University Hospital and Inserm Transfert Enter Collaboration to Identify Novel Therapeutic Targets in Obesity and Metabolic Diseases CI
Evotec Extends Drug Discovery Collaboration With CHDI Foundation for Huntington's Disease MT
Evotec, CHDI Foundation Extend 20-year Partnership for Huntington's Disease Treatments MT
Evotec and CHDI Foundation Extend Strategic Drug Discovery Collaboration in Huntington?s Disease CI
EVOTEC : Deutsche Bank maintains a Buy rating ZD
Evotec Shares Rise Following Gene Therapy Exit, Q1 Results MT
EVOTEC : RBC gives a Buy rating ZD
Transcript : Evotec SE, Q1 2024 Earnings Call, May 22, 2024
Evotec Q1 Net Loss Widens as Revenue Falls MT
Uncertainty at Evotec hampers share price performance DP
Evotec SE Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Evotec exits gene therapy business - slump in earnings at the start of the year RE
EVOTEC : Warburg Research reiterates its Buy rating ZD
EVOTEC : Jefferies keeps its Buy rating ZD
Evotec remains under pressure - 'Too many question marks' DP
EVOTEC : Gets a Buy rating from RBC ZD
Jefferies lowers target for Evotec to 16 Euro - 'Buy' DP
EVOTEC : Jefferies maintains a Buy rating ZD
Chart Evotec SE
More charts
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.4 EUR
Average target price
20.79 EUR
Spread / Average Target
+147.50%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW